NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis $34.94 +0.07 (+0.20%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$34.94 0.00 (-0.01%) As of 06/6/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AtriCure Stock (NASDAQ:ATRC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AtriCure alerts:Sign Up Key Stats Today's Range$34.40▼$35.3350-Day Range$29.07▼$34.9452-Week Range$18.94▼$43.11Volume371,162 shsAverage Volume648,081 shsMarket Capitalization$1.73 billionP/E RatioN/ADividend YieldN/APrice Target$50.67Consensus RatingBuy Company OverviewAtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Read More… AtriCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreATRC MarketRank™: AtriCure scored higher than 70% of companies evaluated by MarketBeat, and ranked 291st out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtriCure has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AtriCure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($0.60) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -36.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -36.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 3.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AtriCure's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.30% of the float of AtriCure has been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AtriCure has recently increased by 1.96%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.30% of the float of AtriCure has been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AtriCure has recently increased by 1.96%, indicating that investor sentiment is decreasing. News and Social Media2.1 / 5News Sentiment0.73 News SentimentAtriCure has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for AtriCure this week, compared to 5 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,600.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AtriCure's insider trading history. Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRC Stock News HeadlinesAtriCure (NASDAQ:ATRC) Stock Rating Lowered by Wall Street ZenJune 1, 2025 | americanbankingnews.comInsider Sell: Vinayak Doraiswamy Sells 2,500 Shares of AtriCure Inc (ATRC)May 31, 2025 | gurufocus.com"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.June 7, 2025 | Crypto 101 Media (Ad)Comparing AtriCure (NASDAQ:ATRC) & Nyxoah (NASDAQ:NYXH)May 31, 2025 | americanbankingnews.comATRC Crosses Below Key Moving Average LevelMay 25, 2025 | nasdaq.comAtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceMay 23, 2025 | businesswire.comAtriCure Q1 2025 presentation: Revenue up 13.6%, raises full-year guidanceMay 9, 2025 | investing.comAtriCure (ATRC) Shares Cross Below 200 DMAMay 2, 2025 | nasdaq.comSee More Headlines ATRC Stock Analysis - Frequently Asked Questions How have ATRC shares performed this year? AtriCure's stock was trading at $30.56 at the start of the year. Since then, ATRC stock has increased by 14.3% and is now trading at $34.94. View the best growth stocks for 2025 here. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) announced its earnings results on Tuesday, April, 29th. The medical device company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.11. The company's revenue was up 13.5% on a year-over-year basis. Read the conference call transcript. Does AtriCure have any subsidiaries? AtriCure subsidiaries include SentreHEART. Who are AtriCure's major shareholders? Top institutional shareholders of AtriCure include Vanguard Group Inc. (9.52%), Alliancebernstein L.P. (7.43%), UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC (4.44%) and Champlain Investment Partners LLC (4.32%). Insiders that own company stock include Salvatore Privitera, Vinayak Doraiswamy, Justin J Noznesky, Karl S Dahlquist, Karen Prange and Maggie Yuen. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD). Company Calendar Last Earnings4/29/2025Today6/07/2025Next Earnings (Estimated)7/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ATRC CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,050Year Founded2000Price Target and Rating Average Stock Price Target$50.67 High Stock Price Target$60.00 Low Stock Price Target$44.00 Potential Upside/Downside+45.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$44.70 million Net Margins-9.61% Pretax Margin-9.39% Return on Equity-6.80% Return on Assets-5.19% Debt Debt-to-Equity Ratio0.13 Current Ratio3.65 Quick Ratio2.62 Sales & Book Value Annual Sales$480.08 million Price / Sales3.60 Cash FlowN/A Price / Cash FlowN/A Book Value$9.46 per share Price / Book3.69Miscellaneous Outstanding Shares49,505,000Free Float47,316,000Market Cap$1.73 billion OptionableOptionable Beta1.59 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:ATRC) was last updated on 6/7/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredPrepare now for May 31 eventPrepare now for June 30 event This man grew up in a trailer in New Mexico. Today, he's a multimillionaire t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.